Navigation Links
DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
Date:4/23/2009

FORT WORTH, Texas, April 23 /PRNewswire/ -- DFB Pharmaceuticals, Inc., has announced the promotion of Maxwell A. Lea, III, to Vice President Business Development and Corporate Finance. Mr. Lea was most recently Director of Corporate Development and Finance for the company.

"Since joining DFB in 2002, Maxwell has positively impacted every level of our company and its affiliate businesses," said Michael A. Patterson, Chief Financial Officer of DFB Pharmaceuticals. "I can say without reservation that our companies have excelled due to his successes."

As Vice President, Mr. Lea will manage DFB's capital raising and financing activities, business development initiatives and strategic planning. He will also be responsible for business development efforts for Healthpoint, Ltd., a DFB affiliate company also based in Fort Worth.

His role for Healthpoint, a branded specialty pharmaceutical company, will be to serve as a member of its senior staff group, managing a team that focuses on further expanding the Healthpoint product portfolio through the acquisition of products and technologies.

Additionally, Mr. Lea has also assumed responsibility for Healthpoint International, with employees in Canada, Puerto Rico and Switzerland and distributors in numerous countries around the globe.

Prior to his career at DFB, Mr. Lea was an investment banker with Banc of America Securities. He received a Bachelor of Arts in Economics from Vanderbilt University and a Master of Business Administration from The Fuqua School of Business at Duke University, where he graduated as a Fuqua Scholar. He has earned the Chartered Financial Analyst (CFA) designation.

DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. DFB's business structure is organized by segments: Branded Pharmaceuticals, Biotechnology, and Pharmaceutical Services. The Branded Pharmaceuticals segment includes HEALTHPOINT, Ltd., active in the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and biotech drugs for wound care indications since 1992. Pharmaceutical Services includes DPT Laboratories, Ltd., a Contract Development and Manufacturing Organization (CDMO) and industry source for semi-solid and liquid development and manufacturing services for the world's leading pharmaceutical, biotechnology, and healthcare companies. The Biotechnology segment encompasses Phyton Biotech, Inc., whose proprietary plant cell culture technology platform is used to develop and manufacture products with applications in pharmaceutical and biotech industries.


'/>"/>
SOURCE DFB Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):